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Summary
Objective: Our present study examined the effect of intra-articular cyclooxygenase-2 (COX-2) inhibitor parecoxib on osteoarthritis (OA) pro-
gression and the concomitant changes in excitatory amino acids’ (EAAs) levels of the anterior cruciate ligament-transected (ACLT) knee joint
dialysates.
Methods: OA was induced in Wistar rats by anterior cruciate ligament transection of the knee of one hindlimb, the other was left unoperated
and untreated. Rats were placed into four groups: Group ACLT/P received intra-articular parecoxib injection (100 mg) in the ACLT knee once
a week for 5 consecutive weeks starting at 8 weeks after surgery. Group ACLT/S received the same procedure as group ACLT/P with saline
injection instead. Na€ıve (Na€ıve/P) rats received only intra-articular parecoxib injection in one knee once a week for 5 consecutive weeks with-
out surgery. The sham-operated rats underwent arthrotomy only without treatment. Twenty weeks after surgery, knee joint dialysates were
collected and EAAs’ concentration was assayed by high-performance liquid chromatography, and gross morphology and histopathology (Man-
kin and synovitis grading) were examined on the medial femoral condyles and synovia.
Results: Parecoxib alone had no effect on cartilage and synovium of normal knees in Na€ıve/P rats. In ACLT/P rats, parecoxib treatment
showed a signiﬁcant inhibition of cartilage degeneration of the medial femoral condyle at both the macroscopic level (1.15 0.17 vs
2.55 0.12, P< 0.05) and the Mankin scores (3.03 0.28 vs 8.82 0.43, P< 0.05). Intra-articular parecoxib injection also suppressed the
synovial inﬂammation of ACLT joint compared to the ACLT/S group (3.92 0.41 vs 9.25 0.32, P< 0.05). Moreover, glutamate and aspartate
levels were also signiﬁcantly reduced in the ACLT/P group compared to the ACLT/S group by parecoxib treatment (91.2 9.4% vs
189.5 17.0%, P< 0.05 and 98.2 11.6% vs 175.3 12.4%, P< 0.05, respectively).
Conclusion: This study shows that intra-articular injection of COX-2 inhibitor parecoxib inhibits the ACLT-induced OA progression; it was ac-
companied by a reduction of glutamate and aspartate concentration in the ACLT joint dialysates. From our present results, we suggested that
intra-articular parecoxib injection, in addition to the anti-inﬂammatory effect, inhibiting the EAAs’ release, may also play a role in inhibiting the
traumatic knee injury induced OA progression.
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SocietyIntroduction
Osteoarthritis (OA), the most common cause of pain and
disability in the elderly, is a complex disease characterized
by bone remodeling, synovium inﬂammation, and cartilage
loss. Although OA is classiﬁed as a noninﬂammatory
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Received 3 August 2006; revision accepted 21 November 2006.63arthropathy, inﬂammation has been shown to play a signiﬁ-
cant role in the disease progression1. Patients with rupture
of the anterior cruciate ligament (ACL) develop post-
traumatic OA of the knee1. Restoration of knee stability
provides symptomatic relief, but does not reduce the degen-
erative changes in the ACL-injured knee2. This suggests
that the development of post-traumatic OA may not only
a purely biomechanical origin but biochemical changes
have may also involve.
Prostaglandins (PGs) are known to play a role in the
pathogenesis of inﬂammation and inﬂammatory pain3.
PGs play peripheral and central roles in inﬂammatory
processes, nociceptor sensitization, and pain generation.8
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they are used to provide analgesia and inhibit inﬂammatory
process4. COX is the rate-limiting step in PGs’ production
and increased COX activity is considered the critical factor
in driving PGs’ synthesis at inﬂammatory sites4. Two iso-
forms of COX have been identiﬁed; the constitutive COX-1
is distributed in most tissues and is responsible for physio-
logical PGs’ production5, while COX-2 is induced in various
cell types, including chondrocytes, when exposed to cyto-
kines, mitogens, and endotoxins6. Conventional nonsteroi-
dal anti-inﬂammatory drugs (NSAIDs) inhibit both COX-1
and COX-2 at standard anti-inﬂammatory dose and this
dual inhibition leads to a number of side effects, in particular
gastrointestinal ulceration7. Cartilage, the target for extracel-
lular matrix destruction in inﬂammatory arthropathies, is the
primary site for pathogenic processes in OA. Cultured chon-
drocytes from OA joints show increased prostaglandin E2
(PGE2) production and COX activity
8. Unstimulated human
chondrocytes do not contain detectable COX-2 mRNA,
but it is induced by interleukin 1b (IL-1b)5. Animal data
show that inhibition of COX-2 provides analgesic and anti-
inﬂammatory effects4.
Glutamate is the main excitatory neurotransmitter in the
synapses of the central nervous system (CNS). Several
studies have shown that excitatory amino acids (EAAs),
such as glutamate and aspartate, actively contribute to
the local regulation of bone metabolism9,10. Animal and clin-
ical studies have shown an increase in glutamate and as-
partate levels in the joint ﬂuid in active arthropathies11,12,
and intra-articular injection of glutamate results in increased
joint blood ﬂow and inﬂammation in joints13. The involve-
ment of EAAs in peripheral nociceptive signal transduction
had been postulated in animal models of acute arthritis14.
A recent study indicated a critical involvement of EAA re-
ceptors in the pathophysiology of arthritic pain15. We previ-
ously reported that glutamate and aspartate levels are
signiﬁcantly increased in the dialysates of ACL-transected
(ACLT) knees, and suggested a role of EAAs in early OA
development16.
Parecoxib, a water-soluble prodrug of the oral formulation
valdecoxib, is approximately 28,000-fold more potent
against COX-2 than against COX-117,18. It is the ﬁrst inject-
able COX-2 inhibitor available18. COX-2 inhibitors are
known therapeutic agents for OA. However, the physiolog-
ical importance of COX-2 and its interaction with glutamate
receptors is still not clearly understood. In this study, by
using a microdialysis technique, we examined the effects
of intra-articular injection of the COX-2 inhibitor parecoxib
on the progression of OA and EAA changes. In this ACLT-
OA animal model, we found that parecoxib reduced the
progression of OA and it was associated with a signiﬁcant
decrease in glutamate and aspartate levels in the dialysates
of ACLT knee joints compared to saline-treated ACLT knees.
Methods
ANIMAL MODEL
The experimental protocol was approved by the Animal
Care and Use Committee of our Institute and conformed
to the guidelines for the care and use of animals in research
of National Defense Medical Center, Taiwan. Thirty-two 3-
month-old-male Wistar rats (body weight 270e325 g) were
used. The surgical procedure was modiﬁed from that de-
scribed by Stoop et al.19 and our previous study16. Cefazo-
lin (20 mg/kg) was given intraperitoneally preoperatively
and every 12 h for 3 days after operation for prophylacticinfection control. Wound healing, infection, and any other
complications were monitored continuously during the 20-
week observation period.
EXPERIMENTAL DESIGN AND COX-2 INHIBITOR PARECOXIB
INJECTION
Eight weeks after surgery, the ACLT rats were divided
into two groups. Rats in the ACLT/P group (n¼ 9) were in-
tra-articularly injected with parecoxib (100 mg in 0.1 ml;
Dynastat, Pﬁzer) in the ACLT knee once a week for
5 weeks, while rats in the ACLT/S group (n¼ 8) were
injected on the same schedule with 0.1 ml saline only.
The sham-operated group (n¼ 9) received arthrotomy
only with no injection. Another six na€ıve rats received
intra-articular parecoxib injection as parecoxib control
(Na€ıve/P group). Twenty weeks after surgery, microdialysis
was performed, then the rats were sacriﬁced and the knees
examined histologically. The experimental protocol is sum-
marized in Fig. 1.
CONSTRUCTION AND PLACEMENT OF THE MICRODIALYSIS
PROBE
Twenty weeks after ACLT or sham operation, a microdial-
ysis probe was implanted in each knee joint under isoﬂur-
ane anesthesia as described above. A 27-gauge needle
attached to a tuberculin syringe was passed through the
joint capsule lateral to the patellar ligament, then the micro-
dialysis probe was inserted through the needle into the
knee joint as described in our previous report16, and its po-
sition was conﬁrmed by X-ray examination. The microdialy-
sis probe16 was constructed using two 5 cm polyethylene
tubes (0.008 inch inner diameter, 0.014 inch outer diameter)
and a 1.5 cm cuprophan hollow ﬁber (300 mm outer diame-
ter, 200 mm inner diameter, 50 kDa molecular weight cut-off;
Filtral, AN 69-HF, Eicom Co., Kyoto, Japan). A 12 cm
Nichrome-Formvar wire (0.0026 inch diameter) was passed
through two 1 cm polycarb tubes (194 mm outer diameter,
102 mm inner diameter) and the cuprophan hollow ﬁber.
The ends of the external silastic tubes were connected to
a syringe pump (CMA-100, CMA/Microdialysis Inc., Solna,
Sweden) for sample collection. The dialysis probe was per-
fused with modiﬁed Ringer’s solution (8.60 mg/ml of NaCl,
0.30 mg/ml of KCl, and 0.33 mg/ml of CaCl2, pH 7.4) at
a ﬂow rate of 5 ml/min. After a 30-min equilibration period,
the dialysate was collected over the next 3 h. All samples
were collected in polypropylene tubes on ice and then fro-
zen at 80C until assayed.
MEASUREMENT OF EAAs
High-performance liquid chromatography (HPLC) with
a ﬂuorescence detector (model 126, Beckman Instruments
Inc., Fullerton, CA, USA) was used for EAA measurement,
as described in our previous report16,20. In brief, a reverse-
phase C-18 column with o-phthaldialdehyde pre-column
derivatization and ﬂuorescence detector was used. Each
sample was injected onto the column and eluted for
20 min at a ﬂow rate of 0.45 ml/min with a linear gradient
from 100% mobile phase A (20 mM sodium acetate, pH
7.2, containing 0.18% triethylamine, and 0.3% tetrahydrofu-
ran) to 75% mobile phase A, 25% mobile phase B (100 mM
sodium acetate/acetonitrile/methanol 1/2/2) in 30 min, then
for 5 min with 100% mobile phase B. Using this protocol,
glutamate, aspartate, serine, taurine and glutamine were
successfully separated. External standards containing 0,
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Fig. 1. Experimental course. ACLT/S (n¼ 8); ACLT/P (n¼ 9); Na€ıve/P (n¼ 6); and sham (arthrotomy without ACLT, n¼ 9). Saline injection:
intra-articular injection of 0.1 ml of saline once a week for 5 consecutive weeks starting at week 8 after surgery. Parecoxib injection: as for the
saline group, but using parecoxib (100 mg/0.1 ml).108, 107, 106, or 105 M standard amino acids were run
before and after each sample group. The detection sensitiv-
ity was 108 M. The recovery rate of the dialysis probe was
25% at an infusion rate of 1 ml/min. The contralateral knee
of rats did not receive any surgery and the concentration
of EAAs of the contralateral knee joint dialysates was de-
ﬁned as 100% as control. All standards and samples were
analyzed in duplicate.
GROSS MORPHOLOGY AND HISTOPATHOLOGICAL
EXAMINATIONS OF KNEE JOINTS
The width of the bilateral hindlimb knee joints was mea-
sured from medial to lateral aspect of joint line by calipers
(AA847R, Aesculap, AG&CO, KG, Germany) before opera-
tion (baseline) and at 4, 8, 12, 16, and 20 weeks after oper-
ation. At week 20 after surgery and microdialysis sample
collection, rats were sacriﬁced under sodium pentobarbital
(50 mg/kg) anesthesia, then perfused intracardially with
heparinized saline (400 ml) followed by freshly prepared
4% paraformaldehyde in 0.1 M phosphate-buffered saline,
pH 7.4. The knees were disarticulated aseptically, then
the joints were cut 0.5 cm above and below the joint line,
stripped of muscle, ﬁxed in 10% neutral buffered formalin
for 2 days, and then decalciﬁed for 7 days in 10% formic
acid, which was changed daily. After X-ray conﬁrmation of
decalciﬁcation, the joints were cut in the midsagittal plane,
washed in running tap water, and parafﬁn-embedded in
an automatic processor (Autotechnicon mono 2, Technicon
Co, Chauncey, NY). Previous studies have demonstrated
that the medial femoral condyles show the most advanced
change following ACLT16,21, so these and associated syno-
via were selected for histological preparation and assess-
ment. Serial articular cartilage sections (5 mm) were cut on
a Leica 2065 rotatory microtome (Leica Instruments, Wet-
zlar, Germany) from the central weight-bearing surface of
the medial femoral condyles of the ACLT and sham-oper-
ated knees. Synovial membrane specimens were carefullydissected from the suprapatellar pouch and the medial tibio-
femoral compartments and 10 slides were prepared from
each knee. Cartilage was stained with hematoxylin/eosin
(H&E) and Safranin-O/fast green stain to assess general
morphology and matrix proteoglycans. All samples were
numbered randomly and evaluated by two blinded ob-
servers to prevent bias. Randomization and numbering
were performed by one assistant who did not participate
in any of the operations, injections, or evaluations. Immedi-
ately after sacriﬁce, each knee was examined for gross
morphologic changes of cartilage lesions of the medial fem-
oral condyle using previously described methods22,23.
Brieﬂy, cartilage erosion was graded on a scale of 0e4
with 0¼ surface appears normal; 1¼minimal ﬁbrillation,
or a slight yellowish discoloration of the surface; 2¼ erosion
extended to the superﬁcial or middle layers; 3¼ erosion ex-
tended to the deep layer; and 4¼ erosion extended to the
subchondral bone. Microscopic examination of the articular
cartilage in the medial femoral condyles was graded ac-
cording to the Mankin’s grading system24; this score as-
sesses structure (0e6 points), cellularity (0e3 points),
matrix staining (0e4 points), and tidemark integrity (0e1
points), and has a maximum of 14 points. The ﬁnal score
for each cartilage was based on the most severe histologic
changes observed in multiple sections from each specimen.
The Mankin score was divided into three stages: stage I
(mild degenerative change, 0e6 points), stage II (moderate
degenerative change, 7e9 points), and stage III (severe de-
generative change, 10 or more points, i.e., cartilage disor-
ganization or complete cartilage loss with extensive
exposure of subchondral bone). The synovium from ACLT
and sham-operated knees of each group was also pro-
cessed, embedded in parafﬁn, and stained with H&E for cel-
lular assessment by histology25; this score assessed (1)
synovial lining layer: hyperplasia of synovial lining cells
(0e3 points), hypertrophy of synovial lining layer (0e3
points), and inﬁltration of inﬂammatory cells (0e3 points);
(2) subsynovial tissue: proliferation of granulation tissue
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inﬂammatory cells (0e3 points), with a maximum of 18
points. The total scores were divided into three stages:
0e6 points (mild synovitis), 7e12 points (moderate synovi-
tis), and 13 or more points (severe synovitis).
DATA AND STATISTICAL ANALYSIS
All data are presented as the mean S.E.M. and analyzed
by one-way ANOVA with Fisher’s post hoc tests for multiple
comparisons. A P value less than 0.05 was considered
signiﬁcant.
Results
One rat showed mild serous discharge from the wound
the third day after ACLT, however, the symptom subsided
after dressing was changed and after 3 more days of antibi-
otics (cefazoline) treatment. No sepsis or hemarthrosis was
observed in the present study. At sacriﬁce, all ACLT knees
showed complete transection of the ACL. The level of daily
activity was similar in the rats of all four groups, and there
were no signiﬁcant differences in body weight between
the groups during the whole study period.
KNEE JOINT INFLAMMATION AND MACROSCOPIC
EVALUATION
Severity of knee joint inﬂammation, reﬂected by an in-
crease in hindpaw knee joint width, was observed at week
20 after ACLT. Figure 2 shows the change in knee joint width
at 20 weeks after surgery compared to before surgery; the in-
crease in jointwidths ofACLT/S,ACLT/P,Na€ıve/Pandsham-
operated groups were 2.31 0.78 mm, 1.09 0.45 mm,
0.10 0.04 mm and 0.12 0.03 mm, respectively. ACLT re-
sulted in a signiﬁcant increase (P< 0.05) in the knee joint
width compared to that of sham-operated and Na€ıve/P rats.
When compared to saline injection, parecoxib signiﬁcantly
reduced joint swelling in ACLT rats (P< 0.05). On gross ex-
amination of the cartilage, the medial femoral condyles
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Fig. 2. Time-course of joint width changes after surgery. The widths
of the bilateral hindlimb knee joints were measured in each rat be-
fore, and at 4, 8, 12, 16, and 20 weeks after surgery. The data
(mean S.E.M.) are expressed as the difference in knee width be-
tween the values at week 20 after surgery and before surgery in
each group. a, P< 0.05 compared to the Na€ıve/P and sham-oper-
ated groups; b, P< 0.05 compared to the ACLT/S group.showed cartilage degeneration with ﬁbrillation, erosion, and
ulcer formation and the macroscopic score was 2.55 0.12
in theACLT/S group (Table I). In theACLT/P rats,minor irreg-
ularity and ﬁbrillated lesions were observed on the medial
femoral condyles and the macroscopic score was
1.15 0.17 (Table I). In the Na€ıve/P and sham-operated
rats, the cartilage on the medial femoral condyles was nor-
mal, with a glistening translucent smooth surface, and no car-
tilage defects or osteophytes were noted, the macroscopic
scoreswere0.25 0.04and0.34 0.12, respectively (Table
I). Signiﬁcant differences on the macroscopic scores were
found between Na€ıve/P and both ACLT/S and ACLT/P
groups (P< 0.05). Similar results were also found between
sham-operated and both ACLT/S and ACLT/P groups (Table
I). Moreover, the grade of cartilage damage in the ACLT/P
group was signiﬁcantly lower than that in the ACLT/S group
(P< 0.05). In OA rats, the synovia from the ACLT/S group
were hypertrophic and showed a reddish yellow discolor-
ation, while, in the ACLT/P rats, the synovia were thinner
and the discoloration less intense. The synovia from the
Na€ıve/Pandsham-operated rats hadawhite luster and trans-
parent appearance and showed neither hyperemia nor evi-
dence of synovitis.
MICROSCOPIC FINDINGS
Specimens from the ACLT/S rats showed ﬁbrillation and
ﬁssures on the cartilage surface, and loss of Safranin-O/
fast green staining and depletion of chondrocytes in carti-
lage layer, and hyperplasia of chondrocytes and decrease
of Safranin-O/fast green staining in the calciﬁed cartilage
layer, and cleft and irregular bony trabeculum between the
junction of calciﬁc cartilage and subchondral layers
[Fig. 3(A)]. In the ACLT/P knee, there was a marked reduc-
tion in the severity of lesions of the medial femoral con-
dyles, only superﬁcial irregularity and mild local ﬁbrillation
extending to the superﬁcial layer of cartilage were ob-
served, and the pericellular Safranin-O/fast green staining
persisted with milder cell loss. Recovery of proteoglycan
and relative normality of chondrocytes in the calciﬁed carti-
lage layer and smooth bony trabeculum in the subchondral
layer was observed [Fig. 3(B)]. The medial femoral con-
dyles of the Na€ıve/P and sham-operated rats showed a nor-
mal histological appearance, with no disruption of cartilage
surface integrity. Preservation of Safranin-O/fast green
staining and chondrocytes in calciﬁed cartilage layer and
smooth bony trabeculum in subchondral layer was also ob-
served [Fig. 3(C,D)]. Moreover, signiﬁcant differences in the
histological OA score were found between the Na€ıve/P
group (1.04 0.15) and both the ACLT/S (8.82 0.43)
and ACLT/P groups (3.03 0.28) (P< 0.05) (Table II). Sim-
ilar results were also observed between the sham-operated
group (1.33 0.26) and the ACLT/S and ACLT/P groups
Table I
Macroscopic evaluation of the articular cartilage of the medial
femoral condyles of the knee joint
Group Score
ACLT/S (n¼ 8) 2.55 0.12a
ACLT/P (n¼ 9) 1.15 0.17a,b
Na€ıve/P (n¼ 6) 0.25 0.04
Sham (n¼ 9) 0.34 0.12
Data are expressed as mean S.E.M. a, P< 0.05 compared to
the Na€ıve/P and sham-operated groups; b, P< 0.05 compared to
the ACLT/S group. The maximum score is 4.
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Fig. 3. Histopathological evaluation of cartilage of the medial femoral condyles (stain, Safranin-O/fast green; original magniﬁcation, 200) and
synovium (H/E stain, original magniﬁcation, 400) of the knee at week 20 after surgery. (A) ACLT/S group showing surface ﬁbrillation (arrow),
chondrocyte loss, and a decrease in Safranin-O/fast green staining intensity, which extends into the radial zone. Cloning of chondrocytes is
apparent in the transitional and radial zones. Decrease of Safranin-O/fast green staining in matrix and hyperplasia of chondrocytes in the cal-
ciﬁed cartilage layer, and cleft and irregular bony trabeculum between junction of calciﬁed cartilage and subchondral layer are observed. (B)
ACLT/P group showing irregularity of the superﬁcial layer of the cartilage (arrow), and mild loss of Safranin-O/fast green staining of the su-
perﬁcial layer of the cartilage. Recovery of proteoglycan and relative normality of chondrocytes in the calciﬁed cartilage layer and smooth
bony trabeculum in the subchondral layer are observed. In (C) Na€ıve/P and (D) sham groups, the superﬁcial layer of cartilage is smooth
and no disruption of surface integrity is observed (arrow). The cartilage matrix is well stained with Safranin-O/fast green. Preservation of Saf-
ranin-O/fast green staining and chondrocytes in calciﬁed cartilage layer and smooth bony trabeculum is observed in subchondral layer. (E)
Synovial membrane from the ACLT/S group, showing hyperplasia of lining cells and hypertrophy of the synovial and subsynovial tissue. Mono-
nuclear cell inﬁltration of the underlying tissues and a ﬁbrinoid exudate (arrow) are also seen. (F) Synovial membrane from the ACLT/P group
shows focal synovitis (arrow) with mild mononuclear cell inﬁltration. Synovial membrane from the (G) Na€ıve/P and (H) sham groups shows no
synovial lining cell hyperplasia (scale bar¼ 100 mm).
643Osteoarthritis and Cartilage Vol. 15, No. 6(P< 0.05; Table II). The Mankin score of the ACLT/P group
was signiﬁcantly lower than that of the saline group
(P< 0.05). The synovia from the ACLT/S group rats were
thick, had focal villi, and showed hyperplasia of the lining
cells, with moderate mononuclear cell inﬁltration
[Fig. 3(E)], while the synovia from the ACLT/P group rats
showed focal synovitis (arrow) with mild mononuclear cell
inﬁltration [Fig. 3(F)]. The histology of the synovia from
the Na€ıve/P and sham-operated rats was normal
[Fig. 3(G,H)]. The synovitis scores are shown in Table II;
the score was signiﬁcantly lower in the Na€ıve/P group
(1.38 0.09, P< 0.05) than that in the ACLT/S group
(9.25 0.32) or in the ACLT/P group (3.92 0.41) (Table
II). Similar results were found between the sham-operated
group (1.82 0.33) and both the ACLT/S and ACLT/P
groups (P< 0.05) (Table II).
EAA LEVELS IN KNEE JOINT DIALYSATES
The mean resting concentrations of glutamate, aspartate,
serine, taurine and glutamine in joint dialysates of the con-
tralateral control rats were 2.01 0.15, 0.33 0.02,
6.12 0.47, 17.52 1.54 and 23.5 1.98 mM (mean -
 S.E.M.), respectively, and they were deﬁned as 100% for
the control basal level. EAA levels in knee joint dialysates
were measured at 20 weeks after surgery in all four groups
taking the levels in the contralateral control knee as the
100% value. No signiﬁcant difference of glutamate and as-
partate in the knee joint dialysates was observed between
bilateral knees in the Na€ıve/P group (data not shown). A
signiﬁcant increase in glutamate level was found in the
ACLT/S group (189.5 17.0%) (P< 0.05) compared to
the Na€ıve/P (89.8 8.4%), sham-operated (109.3 2.3%)
or ACLT/P (91.2 9.4%) group. No difference was ob-
served between ACLT/P, Na€ıve/P (P¼ 0.565) and sham-
operated groups (P¼ 0.487) [Fig. 4(A)]. The differences of
aspartate concentrations were similar to the changes of glu-
tamate; 175.3 12.4% for ACLT/S, 102.5 9.9% for Na€ıve/
P, 104.2 4.1% for sham-operated, and 98.2 11.6% for
the ACLT/P groups [Fig. 4(B)]. Other amino acid levels
such as serine, taurine, or glutamine had no difference
among four groups.
Discussions
This study provides evidence, for the ﬁrst time, that intra-
articular injection of the COX-2 inhibitor parecoxib attenu-
ates the progression of OA in ACLT rats. This is also the
ﬁrst study showing a statistic correlation between the reduc-
tion of glutamate and aspartate levels in ACLT joint dialy-
sates after parecoxib treatment of the severity of OA.
Table II
Histological evaluation of the articular cartilage of the medial
femoral condyles and synovial tissue of the knee
Group Osteoarthritic score Synovitis score
ACLT/S (n¼ 8) 8.82 0.43a 9.25 0.32a
ACLT/P (n¼ 9) 3.03 0.28a,b 3.92 0.41a,b
Na€ıve/P (n¼ 6) 1.04 0.15 1.38 0.09
Sham (n¼ 9) 1.33 0.26 1.82 0.33
Data are expressed as mean S.E.M. a, P< 0.05 compared to
the Na€ıve/P and sham-operated groups; b, P< 0.05 compared to
the saline group. Osteoarthritic score (Mankin score)¼ 0e14; syno-
vitis score¼ 0e18.Breakdown of the cartilage matrix leads to ﬁbrillation, ﬁs-
sures, gross ulcerations, and even full thickness loss of
the joint surface19,26. Knee instability following a complete
tear of the ACL often induces OA accompanied by degrada-
tion of the articular cartilage matrix2,27. In our present study,
both the macroscopic and Mankin scores were signiﬁcantly
lower in the ACLT/P group than in the ACLT/S group. More-
over, reduction in the severity of the structural changes and
loss of Safranin-O/fast green staining were observed in the
ACLT/P group. For OA progression, synovial inﬂammation
was found to play an important role1,28. In the synovium,
the efﬁcacy of NSAIDs is attributed to suppression of neu-
trophil activation and inhibition of inﬂammatory PGs’ synthe-
sis3,29. Amin et al. 29 found up-regulation of COX-2 protein
expression and PGE2 level in the chondrocytes from OA
and rheumatoid arthritis cartilage. Moreover, COX-2 induc-
tion was observed in the chondrocytes of OA joints, which
produces PGs and induces local nociceptors’ sensitization
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Fig. 4. Glutamate and aspartate levels in joint dialysates of ACLT
knees from the four groups. EAA levels in the knee joint dialysates
were measured at week 20 after surgery. The dialysates were col-
lected for 3 h. The mean resting concentration of glutamate and as-
partate in synovial ﬂuid dialysates of the contralateral control rats
were 2.01 0.15 and 0.33 0.02 mM, respectively. The EAA con-
centrations in the contralateral knee, at week 20, were taken as
the basal value (100%) and the glutamate (A) or aspartate (B)
levels in the ACLT knee, Na€ıve/P or sham-operated knee are ex-
pressed as the % differences in EAA concentration from the basal
100%. Data are expressed as mean S.E.M. a, P< 0.05 compared
to the Na€ıve/P and sham-operated groups; b, P< 0.05 compared to
the ACLT/S group. ACLT/S (n ¼ 8); ACLT/P (n ¼ 9); Na€ıve/P
(n¼ 6); and sham (n¼ 9).
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was demonstrated to accelerate cartilage degeneration by
inhibiting proteoglycan biosynthesis30. Selective COX-2 in-
hibitors are effective for OA treatment by attenuating syno-
vial inﬂammation and cartilage destruction4,5.
Parecoxib is a highly selective COX-2 inhibitor and is
used for perioperative analgesia/antiinﬂammation17,18. Par-
ecoxib, the prodrug of valdecoxib, has been developed as
the only COX-2-selective inhibitor available in a parenteral
formulation; it is rapidly metabolized into the active form,
valdecoxib, in the liver after intravenous or intramuscular in-
jection with peak plasma valdecoxib concentration occur-
ring between 30 min and 3.5 h and an elimination half-life
of approximately 8 h31,32. Parecoxib is stable in human
plasma suggesting that nonenzymatic hydrolysis and
plasma esterases or amidases are not involved in amide
hydrolysis to valdecoxib33. However, the exact mechanism
and the pharmacokinetics of parecoxib in the joint still need
further investigation. In our present study, intra-articular
parecoxib injection inhibited the progressive cartilage
destruction and the associated synovia inﬂammation. This
parecoxib treatment only stopped the continuous destruc-
tion on the cartilage, but did not reverse the developed
cartilage damage.
An important ﬁnding of our present study was the signiﬁ-
cant reduction of glutamate and aspartate levels in the joint
dialysate by the parecoxib injection compared to the saline
group. Mechanical regulation of glutamate transporter ex-
pression in bone has recently been described34, it suggests
a role of EAAs in paracrine intercellular communication in
bone10. Free radicals are intermediate products in COX-
mediated PGs’ synthesis and are known to be involved in
N-methyl-D-aspartate (NMDA) receptor-mediated glutamate
excitotoxicity35, and PGs produced in the COX pathway
were demonstrated to stimulate Ca2þ-dependent glutamate
release in cultured astrocytes36. Moreover, intra-articular in-
jection of EAA results in thermal hyperalgesia and mechan-
ical allodynia, which are attenuated by local injection of
NMDA or non-NMDA receptor antagonists11. Pain in the
OA knee might result not only from mechanical stimuli,
but also from neurogenic inﬂammation37. The OA-associ-
ated pain may also result from glutamate release from
axons innervating the inﬂamed region38. Injection of kao-
lin/carrageenan mixture into the knee joint induced an im-
mediate increase in glutamate and aspartate levels in the
joint and persisted for hours11. Moreover, in inﬂamed ar-
thritic knees, an increase of glutamate concentration was
observed not only in the axons in the inﬂamed region14,
but also in the synovial ﬂuid12. Endogenous glutamate
was found in intracellular vesicular constituents associated
with vesicular glutamate transporter isoenzyme-1 (VGLUT-
1), and activation of alpha-amino-3-hydroxy-5-methyl-4-
isoxazole-propionic acid (AMPA) receptors, which were
expressed in cultured rat costal chondrocytes, will release
glutamate39. In our laboratory, we have demonstrated
VGLUT-1 and -2 protein expression in cartilage, synovium
and meniscus tissues in Wistar rat knee. It suggests that
cartilage, synovium and meniscus may release glutamate
by ACLT of knee (unpublished observation). Functional
NMDA receptors have been found in a number of bone
cells, including rat and human osteoblasts and osteoclasts,
MG-63 osteosarcoma cells, and bone marrow megakaryo-
cytes9,10. Moreover, glutamate has been reported to medi-
ate intercellular communication in bone cells and
contributes to bone matrix regulation40. It is important to
evaluate the effects of drugs for treating OA on the patho-
physiological processes that occur in this disease, suchas bone changes, synovial inﬂammation, and, in particular,
cartilage destruction. The present study is the ﬁrst to dem-
onstrate that intra-articular injection of parecoxib inhibits
the OA progression in association with a reduction of gluta-
mate and aspartate concentration in the dialysates of the
ACLT knee. However, our present results do not exclude
the contribution of other biological substances in the OA
knee joint.
In conclusion, our results show that COX-2 inhibitor par-
ecoxib reduces the ACLT-induced OA progression as dem-
onstrated by the reduction in synovitis and cartilage
damage, and the reduction of glutamate and aspartate
levels in ACLT joint dialysate after parecoxib treatment.
The inhibition of the inﬂammatory process during the early
phase of OA can be enough to account for a further im-
provement of cartilage lesions. These ﬁndings provide
a valuable contribution to the development of new therapeu-
tic strategies for OA. The role of glutamate in OA develop-
ment remains a mystery and further investigation is
needed to better understand the effect of selective COX-2
inhibitors on OA progression and the role of EAAs in OA
development.
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